TB Epidemiology and Intervention Research Unit

Outputs

Publications

1. G Louwagie, B Girdler-Brown, R Odendaal, T Rossouw, S Johnson, M Van der Walt. Missed opportunities for accessing HIV care among Tshwane tuberculosis patients under different models of care. Running head: Antiretroviral treatment access for TB patients. Int J Tuberc Lung Dis. Int J Tuberc Lung Dis 2012; Aug; 16(8):1052-1058.
2. Alyssa Finlay, Joey Lancaster, Timothy H Holtz, Karin Weyer, Abe Miranda and Martie van der Walt. Patient- and provider-level risk factors associated with default from tuberculosis treatment, South Africa, 2002: a case-control study. BMC Public Health 2012, 12:56 (20 January 2012).
3. J. E. Farley, C. Tudor, M. Mphahlele, K. Franz, N. A. Perrin, S. Dorman, M. Van der Walt. A national infection control evaluation of drug-resistant tuberculosis hospitals in South Africa. Int J Tuberc Lung Dis 16(1):82–89. Published Jan 2012.
4. Ashwin S. Dharmadhikari, Randall J. Basaraba, Martie L. Van Der Walt, Karin Weyer, Matsie Mphahlele, Kobus Venter, Paul A. Jensen, Melvin W. First, Sydney Parsons, David N. McMurray, Ian M. Orme, Edward A. Nardell, Natural infection of guinea pigs exposed to patients with highly drug-resistant. Tuberculosis (2011), Tuberculosis (Edinb). 2011 Jul;91(4):329-38.
5. Farley J.E, Ram M, Pan W, Waldman S.M, Cassell, G.H, Chaisson R, Weyer K, Lancaster J, Van der Walt M. Outcomes of Multi-drug Resistant Tuberculosis (MDR-TB) Amongst a South African Anti-retroviral Naïve Cohort with High HIV Prevalence. PLoS One. 2011; 6(7): e20436. Published online 2011 July 22.
6. S Mahomed, M Holst, M Uys, M van der Walt, SE Knight. Success of an integrated tuberculosis and HIV/IDS project in 2009 in Uthukela District, KwaZulu-Natal. SAMJ July 2011, Vol 101, No. 7.
7. C Kvasnovsky, M vd Walt, KK Thomas, R Erasmus, O Siwisa. Extensively drug-resistant TB in Eastern-Cape, South Africa: High Mortality in HIV Negative and HIV positive patients. Journal of Acquired Immune Deficiency Syndromes: 1 June 2011 - Volume 57 - Issue 2 - pp 146-152.
8. Ashwin S. Dharmadhikari, Anton Stoltz, Ed Nardell, P Jensen, Kobus Venter, Matsie Mphahlele, Martie van der Walt. Surgical Face Masks worn by Multidrug-Resistant Tuberculosis Patients: Impact on Infectivity of Air on a Hospital Ward. Am J Respir Crit Care Med. 2012 May 15;185(10):1104-9 Epub 2012 Feb 9.
9. Dick Menzies, et al. "Multidrug-resistant tuberculosis treatment regimens and patient outcomes:  an Individual Patient Data (IPD) Meta-Analysis of 9153 patients." Submitted to PLoS Medicine.
10. Lieketseng Masenyetse; Samuel Manda; Joey Lancaster; Martie van der Walt "Investigating Excess Mortality among Multidrug Resistant Tuberculosis Patients Co-infected with HIV in South Africa". Submitted to Plos One.
11. Chapter published: "The Antiquity and history of medicinal plants and tuberculosis" by SPN Mativandlela and N Lall. page no 62 – 90. Book: Herbal drugs, A modern approach to understand them better. New Central Book Agency , Kolkata, Author: Subhash C Mandal.
12. Semete, B., Booysen, L.I.J., Kalombo, L., Venter, J.D., Katata, L., Ramalapa, B., Verschoor, J.A., Swai, H. 2010. In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. Toxicol Appl Pharmacol. 249(2): 158-165. 
13. Dheda K, Shean KP, et al, Kvasnovsky C, Van der Walt ML. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010 May 22:375(9728):1760-1. 
14. Jarand J, Shean K, O’Donnel M, Loveday M, Kvasnovsky C,  Van der Walt M, Adams S, Willcox P, O’Grady J, Zumla A, Dheda K. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa, Tropl Med Int Health 2010 Oct; 15(1): 1179-84.
15. Martie van der Walt, Peter Kantor and Margaret S Westaway, Ethical and legal dilemmas in managing drug-resistant tuberculosis (M/XDR-TB) in South Africa. Submitted to the International Journal of Lung Disease in December 2009.
16. Julie Jarand, Karen Shean, Marian Loveday , Charlotte Kvasnovsky, Martie Van der Walt, Max O’Donnell, Paul Willcox and Keertan Dheda. High Mortality among South African Health Care Workers with Extensively Drug-Resistant Tuberculosis. Submitted to JAMA in September 2009.
17. O'Donnell MR, Jarand J, Loveday M, Padayatchi N,  Zelnick J, Werner L, Naidoo K, Master I, Osburn G, Kvasnovsky C, Shean K, Pai M, Van der Walt M, Horsburgh CR, Dheda K. High Incidence of hospital admissions with multidrug resistant and extensively drug-resistant tuberculosis among South African Health Care Workers. Ann Inter Med 2010 Oct 19; 153(8):516 – 22.
18. Dheda K, Shean KP, Kvasnovsky C, Van der Walt ML et al., 2009. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010 May 22:375(9728):1760-1.  
19. S.P.N. Mativandlela, T. Muthivhi, H. Kikuchi, Y. Oshima, C. J. Hamilton, A.A.H. Hussein, M. L. Van der Walt, P. J. Houghton, N, Lall. Antimycobacterial flavonoids Isolated from the Leaf Extract of Galenia africana. J. Nat. Prod, 2009, 72 (12), pp 2169-2171.
20. S.P.N. Mativandlela, N. Lall. The antiquity and history of medicinal plants and tuberculosis. submitted as a chapter to be in a book.
21. A Labuschagné, N. Lall, S.P.N. Mativandlela, L.J. McGaw, C. Hamilton. Antimycobacterial activity of seven herbaceous plants. 2009; South African Journal of Botany 75(2) 409.
22. Stavrum R, Mphahlele M, Øvreås K, Muthivhi T, P. Bernard Fourie, Weyer K and Harleen M. S. Grewal. High diversity of Mycobacterium tuberculosis genotypes in South Africa. Journal of Clinical Microbiology, June 2009, p 1848-1856, Vol. 47, No. 6.
23. Mphahlele, M Syre H, Valvatne H, Stavrum R, Mannsåker T, Muthivhi T, Weyer K, Fourie B, and Grewal HM. Pyrazinamide resistance among South African multi-drug resistant Mycobacterium tuberculosis isolates. J Clin Microbiol, 2008 Oct; 46(1):3459-64.
24. Cobelens FG, Heidal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, Rieder HL, Weyer K, Zignol M, Working Group on MDR-TB of the Stop TB Partnership. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 2008. Jul 8; 5(7):e150.
25. Mativandlela SPN, Meyer JJM, Hussein AA, Houghton, Hamilton PJC, Lall M. Activity against Mycobacterium smegmatis and M. tuberculosis by extracts of some South African medicinal plants. Phytother Res. 2008 Jun; 22(6):841-5.
26. Wallis RS, Weyer K, Fourie PB . Acquired rifamycin resistance: pharmacology and biology. Expert Rev Anti Infect Ther. 2008 Apr; 6(2):223-30.
27. Mahapatra A, Mativandlela SPN, Binneman B, Fourie PB, Hamilton PJC, Meyer JJM, Van der Kooy F, Houghton P and Lall N. Activitity of 7-methyljuglone derivatives against Mycobacterium tuberculosis  and a subversive substrates for mycothiol disulfide reductase. Bioorganic & Medicinal Chemistry. 15 Dec 2007; 15;24: 7638-7646.
28. Weyer K, Brand J, Lancaster J, Levin J, van der Walt M. Determinants of multidrug-resistant tuberculosis in South Africa: results from a national survey. South African Medical Journal, 2007 Koornhof Festschrift supplement to the SAMJ, Nov 2007, Vol. 97, Nr 11.
29. Wells CD, Cegielski JP, Nelson L, Laserson KF, Holtz T, Finlay A, Castro K, Weyer K. HIV Infection and multidrug-resistant tuberculosis – the perfect storm.  Invited review paper.  Journal of Infectious Diseases 2007; Aug 15; 196 Suppl 1: S86 – 107.
30. Weyer K. Case study: South Africa. Bulletin of the World Health Organization 2007; 85(5): 391-392.
31. Bapela NB, Lall N, Fourie PB, Franzblau SG, Van Rensburg CE. Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis. Phytomedicine. 2006; 13(9-10):630-5.
32. Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe, L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006; Jun;10(6): 649-655.
33. Tsiouris SJ, Austin J, Toro P, Coetzee D, Weyer K, Stein Z, El-Sadr WM. Results of a tuberculosis-specific IFN-gamma assay in children at high risk for tuberculosis infection. Int J Tuberc Lung Dis 2006; Aug; 10(8):939-41.
34. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML Fraser HS, Alarcon E, Cegielski JP, Grzemska M, Gupta R, Espinal M.  Speaking the same language:  treatment outcome definitions for multidrug-resistant tuberculosis.  Int J Tuberc Lung Dis 2005; Jun;9(6): 640-645.
35. Lall N, Meyer JJ M, Y. Wang, NB Bapela, Van Rensburg CEJ, PB Fourie, and Franzblau SG. Characterisation of intracellular activity of antitubercular constituents from the roots of  Euclea natlensis. Pharmaceutical Biology 2005; 43:353-357.
36. Laserson KF, Binkin NJ, Thorpe LE, Laing R, Iademarco MF, Bloom A, Agerton TB, Nelson L, Cegielski JP, Ferroussier O, Holtz T, Vitek E, Gammino V, Tan K, Finlay A, Dewan P, Miranda A, Aquini G, Weyer K, Sy DN, Vernon A, Becetta J, Ershova J, Wells CD.  Capacity building for international tuberculosis control through operations research training.  Int J Tuberc Lung Dis 2005; Feb;9(2): 145-159.
37. Robberts FJ, Chalkley LJ, Weyer K, Goussard P, Liebowitz LD.  Dihydropterate synthase and novel dihydrofolate reductase gene mutations in strains of Pneumocystis jirovecii in South Africa.  J Clin Micro 2005; Mar;43(3):1443-4.
38. Bopape MC, Steel H., Cockeran R, Matlola NM, Fourie PB and Anderson R. Antimicrobial activity of clofazimine is not dependent on C-type phospholipases. Journal of Antimicrobial Chemotherapy 2004; 53: 971-974.
39. Mwinga A, Fourie PB.  Prospects for new anti-tuberculosis treatment in Africa.  Trop Med Int Health 2004; 9:827-832.
40. Blomberg B, Fourie PB.  Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.  Drugs 2003; 63:535-553.
41. The WHO/IUATLD Working Group on Antituberculosis Drug Resistance Surveillance.  Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network:  five rounds of proficiency testing 1994-1998.  Int J Tuberc Lung Dis 2002: (748-756).  (K Weyer – Contributor as Head of SRL for Africa).

Non-peer reviewed journal articles

1. Weyer K. Multidrug-resistant tuberculosis. Continuing Medical Education Journal (CME) 2005; 23(2):  74-84.
2. Weyer K.  Tuberculosis and HIV in Southern Africa.  African Health Care Journal 2004; 2: 6-9.

Books and equivalent publications

1. World Health Organization. New Technologies for Tuberculosis Control: A framework for their adoption, introduction and implementation: WHO: Geneva, 2007. (K Weyer – Member of Stop TB Partnership Task Force on Retooling).
2. World Medical Association.  International Internet Training Course on Management of Multidrug-resistant Tuberculosis.  WMA:  Ferney-Voltaire, 2005, 12 modules. (K Weyer – Author).
3. World Health Organization.  Guidelines for the Management of Drug-Resistant Tuberculosis.  WHO/CDS/TB/2007. World Health Organization:  Geneva.  (K Weyer – Member of Writing Committee and Co-author of Chapter on Laboratory Services).
4. Weyer K.  Multidrug-resistant tuberculosis.  In:  Management of Tuberculosis. Foundation for Professional Development, South African Medical Association:  Pretoria, 2004.
5. Weyer K, L Mvusi.  Transmission and pathogenesis of tuberculosis.  In:  Management of Tuberculosis. Foundation for Professional Development, South African Medical Association:  Pretoria, 2004.
6. Weyer K, R Matji.  Epidemiology and control of tuberculosis.  In:  Management of Tuberculosis. Foundation for Professional Development, South African Medical Association:  Pretoria, 2004.
7. Weyer K, R Matji.  Tuberculosis treatment.  In:  Management of Tuberculosis. Foundation for Professional Development, South African Medical Association:  Pretoria, 2004.
8. Weyer K (ed)  Management of Tuberculosis. Foundation for Professional Development, Medical Association of SA:  Pretoria, 2004, 302 pages.
9. World Health Organization.  Anti-Tuberculosis Drug Resistance in the World.  Report No.3.  The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance.  WHO/HTM/TB/2004.343.  World Health Organization:  Geneva, 2004.  128 pages.  (Weyer K – Member of Writing Committee).
10. Weyer K, Van der Walt M, Lancaster J.  DOTS-Plus for Standardised Management of Multidrug-resistant (MDR) Tuberculosis Patients in South Africa.  3rd Ed.  Pretoria: Directorate TB Control, Department of Health, 2004.    
11. Aziz MA, Fatoumata B, Becx-Bleumink M, Bretzel G, Humes R, Iademarco MF, Kim SJ, Lamothe F, Paramasivan CN, Ridderhof J, Sloutsky A, Van Deun A, Vohra-Shah K, Weyer K.  External Quality Assessment for AFB Smear Microscopy.  APHL:  Washington, 2002, 111 pages  (K Weyer – WHO representative and Member of Writing Committee).

Editorials

1. Fourie PB.  Dealing with HIV-associated tuberculosis at the community level.  Int J Tuberc Lung Dis 2003; 7 (Supplement): S4.
2. Fourie PB, Ellner JJ.  Immunotherapy in the treatment of tuberculosis.  Lancet 2002; (invited - in press).
3. Fourie PB, Ellner JJ, Johnson JL. Whither Mycobacterium vaccae--encore. Lancet 2002; 360(9339):1032-1033.

Policy documents

1. Van der Walt M, Mphahlele M. Upper room ultraviolet air disinfection shown to reduce transmission of multidrug resistant (MDR) tuberculosis under South African hospital conditions: Medical Research Council, 2009(MRC Policy Brief).

Science communication and research translation

1. 2010 Van der Walt ML. March  - May 2010: Series of 4 articles in DENOSA magazine, information pamphlets  and electronic publication on SA Health-net for health care workers on XDR-TB.
2. 2010 Van der Walt ML. March 2010: World TB Day television and radio appearances
3. Van der Walt ML. Upper room ultraviolet air disinfection shown to reduce transmission of multidrug resistant (MDR) tuberculosis under South African hospital conditions.
4. 2009 Van der Walt ML. More tuberculosis, more research. Web and Media Technologies, eHealth Research and Innovation Platform.
5. 2009  Van der Walt ML.  Upper room ultraviolet air disinfection shown to reduce transmission of multidrug resistant (MDR) tuberculosis under South African hospital conditions. South African Medical Research Council (MRC). 2009.
6. Van der Walt ML. http://audio.mrc.ac.za/stream/src/m3u/Tuberculosis-DrMartie-March2009-Part1.mp3
7. Van der Walt ML. http://audio.mrc.ac.za/stream/src/m3u/Tuberculosis-DrMartie-March2009-Part2.mp3
8. Van der Walt ML. http://audio.mrc.ac.za/stream/src/m3u/Tuberculosis-Dr Martie-March2009-Part3.mp3
9. Van der Walt ML. Radio Sonder Grense 24 March 2009 “Statistiek en Navorsing ”Translated “Statistics and research”
10. Van der Walt ML. MedFM 29 June 2009 “Tuberculose, navorsing en behandeling” Translated “TB, research and treatment”.
11. Van der Walt ML. More tuberculosis, more research. Web and Media Technologies, eHealth Research and Innovation Platform. 2009.
12. 2008 Van der Walt ML. Rapid tests for drug-resistant TB to be made available in developing countries. 30 June 2008.
13. 2008 Van der Walt ML. XDR-TB to be tackled extensively. March 2008.
14. 2008 M Sewpersadh, ML Van der Walt, J Leballo, A Jefthas and the staff of Tshepong TB Hospital. Interviews with a healthcare worker and patients participating in the Rapid MDR-TB demonstration project in South Africa. A video production, 2008.
15. Van der Walt ML. XDR-TB to be tackled extensively. March 2008.
16. 2008 Van der Walt ML. Rapid tests for drug-resistant TB to be made available in developing countries. 30 June 2008. South African Medical Research Council (MRC), Foundation for Innovative New Diagnostics (FIND), the National Health Laboratory Service (NHLS) and Department of Health.
17. 2007 K Weyer, ML Van der Walt. FIND, the SAMRC and NHLS seal MOU to begin trial of two new tests for MDR-TB in South Africa, Pretoria, South Africa and Geneva, Switzerland, 12 March 2007.
18. Weyer K, M van der Walt M, Adv. P Kantor. Managing Multidrug-Resistant Tuberculosis – Legal Implications. Medical Research Council, 2006 (MRC Policy Brief).
19. 2005 ML Van der Walt & The DOTS-Plus Study Group of South Africa: Me and my MDR-TB – a Patient information pamphlet.
20. Van der Walt M, Weyer K, Kantor P.  Legal Dilemmas in Management of Multidrug-resistant Tuberculosis in South Africa.  Pretoria:  Medical Research Council, 2004 (MRC Policy Brief).
21. Weyer K.  Performance Standards for Tuberculosis Laboratory Services in South Africa.  Pretoria:  Medical Research Council, 2003.

Non- Peer reviewed conference proceedings and abstracts

1. R Odendaal. High levels of resistance to first and second-line drugs among MDR-TB patients with favourble previous TB treatment outcomes in South Africa.To be presented at 2011 ATS Inernational Conference in Denver, Colorado. 17 May 2011.
2. ML van der Walt. Preserving second-line anti-tuberlosis drug tgreatment for M(X)DR-TB. Presented at Mpumalanga Tuberculosis Control Programme Research Symposium, 8 December 2010, Nelspruit, Mpumalanga.
3. P Mativandlela. Second-line drug-resistance among multidrug-resistant tuberculosis (MDR-TB) failure cases in South Africa. Presented at Mpumalanga Tuberculosis Control Programme Research Symposium, 8 December 2010, Nelspruit, Mpumalanga.
4. M Mphahlele, Systematic evaqluation of infection control at M(X)DR-TB Hospitals. Presented at Mpumalanga Tuberculosis Control Programme Research Symposium, 8 December 2010, Nelspruit, Mpumalanga.
5. Odendaal R, Lancaster J, van der Walt M. The effect of terizodone-based standardised treatment on culture-conversion for HIV-co-infected MDR-TB patients in South Africa. Poster presentation at Mpumalanga Tuberculosis Control Programme Research Symposium, 8 December 2010, Nelspruit, Mpumalanga.
6. Van der Walt M, Lancaster J, Weyer, et al. Two-year follow-up patients with multidrug-resistant (MDR-TB) in South Africa. Mpumalanga Tuberculosis Control Programme Research Symposium, 8 December 2010, Nelspruit, Mpumalanga.
7. Van der Walt M, Lancaster J, Weyer. Mortality among patients with multidrug-resistant tubercolosis (MDR-TB) in South Africa.
8. Lancaster J, Odendaal R, van der Walt M. Risk factors for treatment failure among multidrug-resistant tubercolosis (MDR-TB) in South Africa. Mpumalanga Tuberculosis Control Programme Research Symposium, 8 December 2010, Nelspruit, Mpumalanga.
9. GMC Louwagie, BV Girdler-Brown, R Odendaal, S Johnson, TB Rossouw, M van der Walt, LN Dzikiti, A Stoltz. Presented at 6th PHASA 2010 Conference, East London, 29 November 2010 – 1 December 2010.
10. C L Kvasnovsky, JP Cegielski, R Erasmus, NO Siwisa, K Thomas, M van der Walt. High Mortaqlity in HIV positive and HIV-negative patients with XDR-TB in Eastern Cape Province, South Africa. Poster presentation at 41st IUATLD Conference, 11 – 15 November 2010, Berlin, Germany.
11. J Brand, R Odendaal, J Lancaster, M Sewpersadh, J Farley, ML van der Walt. Second-line drug-resistance among multidrug-resistant tuberculosis (MDR-TB) failure cases in South Africa. Poster presentation at 41st IUATLD Conference, 11 – 15 November 2010, Berlin, Germany.
12. M Sewpersadh, R Odendaal and M van der Walt. Mutation patterns conferring rifampicin and isoniazid resistance to Mycobacterium tuberculosis strains from South Africa. Presented at TSRU meeting, 14 – 16 April 2010, Berlin, Germany.
13. ML van der Walt, Odendaal R, Becker P & Lancaster J. Side effects of terizodone, cycloserine and ethambutol for HIV co-infected MDR0TB patients in South Africa and impact in time-to-conversion. Presented at TSRU meeting, 14 – 16 April 2010, Berlin, Germany.
14. MK van der Walt.  National Jewish Health, University of Pretoria TB Course, 27 August, 2010.
15. M van der Walt. Treatment regimens for XDR-TB in SA. 7th Annual Symposium on diseases relevant to SA hosted by the North West University on 16 and 17 July 2010.
16. M van der Walt. Prevalence of drug-resistance at the initiation of second-line treatment and the existence of TDR. Presented at Institute of Medicine's Forum on Drug Development and Translation, the Academy of Science of South Africa, workshop on Emerging Threat of Multidrug-Resistant Tuberculosis: Global and Local Challenges and Solutions. Roode Vallei Country Lodge Pretoria, South Africa 3 – 4 March 2010.  Roode Vallei Country Lodge Pretoria, South Africa.
17. SPN Mativandlela, D Kalman, G Benian, D Liotta: Preliminary Evaluation of compounds for anthelminthic infection. 4th MRC Research Day, South African Medical Research Council, Cape Town. 2010.
18. M van der Walt, R Odendaal, P Becker & J Lancaster. Sputum conversion and tolerability of terizodone, cycloserine and ethambutol regimens for MDR-TB patients in South Africa. Astra Zenica Day. February 2010. Cape Town.
19. SPN Mativandlela, KV Venter, ML Van der Walt: Pre-clinical platform for the evaluation of new tuberculosis vaccines and drugs. 3rd MRC Research Day, South African Medical Research Council, Cape Town. 2009.
20. M Mphahlele. M van der Walt. Assessing the efficacy of upper room germicidal ultraviolet air disinfection on MDR-TB transmission in a South African hospital.  1st African Congress on Infection Prevention and Control (IPCAN). Kampala, Uganda. 21 – 23 September 2009.
21. Sewpersadh M, Sturm AW. Immune components involved in self-limitation of genital herpes. Oral presentation, FIDSSA (Foundation of infectious diseases societies of southern Africa. Sun City, SA. 20 – 23 August 2009.
22. Max R O’Donnell, Julie Jarand, Marian Loveday, Nesri Padayatchi, Motasim Badri, C. Robert Horsburgh, Karen Shean, Jennifer Zelnick, Martie Van der Walt, Kasavan Naidoo, Iqbal Master, Garth Osburn, Keertan Dheda. High Incidence of Multidrug Resistant and Extensively Drug Resistant Tuberculosis among South African Health Care Worker. Presented at the ASM Conference, Cape Town, South Africa, July 2009.
23. M Sewpersadh, L Mvusi and G Coetzee. A successful model to ensure rapid uptake of a new diagnostic test into policy and practice: rapid diagnosis of MDR-TB in SA. Presented at the TB Colloquium, Cape Town, 3 – 4 June 2009.
24. SPN Mativandlela, K. Venter. N Lall. Antimycobacterial activity of isolated compounds and a novel new chalcone from Galenia Africana. Presented at the TB Colloquium, Cape Town, 3 – 4 June 2009.

Peer reviewed conference proceedings and abstracts

1. J Brand, M Sewpersadh, R Odendaal, J Lancaster, Jason Farley, ML van der Walt. Second-Line Drug-Resistance profiles among failure cases of multidrug-resistant tuberculosis (MDR-TB) treatment in South Africa. Presented at 2nd TB Conference, Durban, South Africa, 1 – 4 June 2010.
2. C Kvasnovsky.  Effect of second-line drug resistance on treatment outcome among MDR-TB patients in PETTS study. Presented at 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cancun, Mexico, 3 – 7 December 2009.
3. C Kvasnovsky, E van Rooyen, O Siwisa, R Erasmus, H October, BA Lujabe, MAJ Molla, C Pistorius, K Thomas, ML van der Walt. Effect of addition of moxifloxacin to XDR-TB treatment regimen in Eastern Cape Province, South Africa. Presented at 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cancun. Mexico, 3 – 7 December 2009.
4. C Kvasnovsky CL, Dalton TL, Ramjee A, Master I, Brand J, Odendaal R, Lancaster J, Cegielski JP. Effect of drug resistance on treatment outcome among MDR-TB patients in Kwazulu Natal Province, South Africa. Presented at 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cancun. Mexico, 3 – 7 December 2009.
5. M vd Walt, M Barnard, L Matsoso H Albert, R O’Brien, M Sewpersadh, G Coetzee. Benefits to Multidrug-resistant tuberculosis (MDR-TB) patients derived from rapid diagnosis by line by line-probe assay (LPA). Presented at 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cancun. Mexico, 3 – 7 December 2009. Poster.
6. M Sewpersadh, G Coetzee, L Matsoso, M Barnard, H Albert, R O’Brien, M van der Walt. The evaluation of Line Probe Assay for routine diagnosis of multidrug-resistant MDR-TB in South Africa.  Presented at 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cancun. Mexico, 3 – 7 December 2009.
7. Akexander H, Dalton TL, Sitti W, Kummik T, Skenders G, Van der Walt M, Asencios L, O’Brien R. Evaluation of the GenoType® MTBRplus assay for detection of rifampicina and isoniazida resistance in clinical isolkates from six countries. Presented at 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cancun. Mexico, 3 – 7 December 2009.
8. Dalton TL, Kliiman KI, Leimane V, Yagui M, Tupasi T, Erokhin V, Van der Walt M, Akksilp S, Kim H, Cegielski JP. Prevalence of drug resistance at the initiation of second-line therapy among MDR-TB patients in 8 countries in the “Preserving Effective TB Treatment Study” (PETTS). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco, CA.
9. M van der Walt, SPN Mativandlela. Pre-clinical platform for the evaluation of new tuberculosis vaccines and drugs. Advanced Design and Development of potential Drugs against Tuberculosis. Pretoria. 3 – 5 August 2009.
10. M Sewpersadh, Coetzee G, Matsoso L, Barnard M, Albert H, O’Brien R, M Van der Walt. Line probe assays (LPA) for programmatic identification of MDR-TB: Retooling challenges and benefits. Tuberculosis Surveillance Research Unit, Seoul, South Korea April 2009.
11. M Mphahlele, E Nardell, A Dharmadhikari, K Venter, M First, K Weyer, M van der Walt, Sidney Parsons, P Jensen: Assessing the efficacy of upper room germicidal ultraviolet air disinfection on MDR-TB transmission in a South African hospital. Tuberculosis Surveillance Research Unit, Seoul, South Korea. April 2009.
12. J Lancaster, M Van der Walt, R Odendaal. Baseline Indicators for the diagnoses of TB in HIV infected patients. Presented at: 4th AIDS Conference, Durban, South Africa. April 2009
13. R Odendaal, J Lancaster, M van der Walt, P Becker. The effect of Terizodone-based standardised treatment on culture-conversion for HIV-coinfected MDR-TB patients in South Africa. Presented at: 4th AIDS Conference, Durban, South Africa. April 2009.
14. M Uys and K Weyer. That’sit: Integrated TB-HIV care: bridging programmes, strengthening systems. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
15. A Dharmadhikari, M Mphahlele, K Venter, K Weyer, SA Parsons, P Jensen, M First, E Nardell. Infectiousness of drug-resistant TB patients then and now: Riley revisited. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
16. AS Dharmadhikari, R Basaraba, G Palanisamy, K Venter, P Jensen, M First, S Parsons, M Mphahlele, K Weyer, D McMurray, E Nardell. Limited Disease Despite Tuberculin Skin Test Positivity Among Guinea Pigs Naturally Exposed to MDR-TB Patients. 2nd Annual New England TB Retreat which was held on June 2, 2008.
17. WA Germishuizen, TN Muthivhi, L Venter, PB Fourie. A rapid, single step bioluminescence technique for the determination of viability of BCG vaccine. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
18. M van der Walt, G Coetzee, A Albert, K Matsoso, M Barnard, M Sewpersadh, R O’Brien. Impact and benefit of rapid diagnosis of MDR-TB through the Genotype(R) MTBDRplus assay in South Africa. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
19. T Dalton, Weyer K, van der Walt M, Brand J, Lancaster J, P Cegielski et al. Prevalence of second-line drug resistance among MDR-TB patients in 7 countries in the PETTS study. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
20. T Dalton, Weyer K, van der Walt M, Brand J, Lancaster J, P Cegielski et al. Genotypic diversity among Mycobacterium tuberculosis isoplates from the “Preserving Effective TB Treatment Study (PETTS) in 6 countries. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
21. TN Muthivhi, SV Omar, H Said, A Osman, WA Germishuizen, P Mativandlela, L Venter, A Hoosen, PB Fourie. Novel light-microscope attachment (Lumin) for diagnosing TB by fluorenscence microscopy. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
22. CL Kvasnovsky, TL Dalton, JL Lancaster, JD Brand, JP Cegielski, ML van der Walt. Early mortality among MDR- and XDR-TB patients in KwaZulu Natal Province, South Africa. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
23. SPN Mativandlela, T Muthivhi, N Lall, JJM Meyer. The evaluation of some South African plants against Mycobacterium species for treatment of tuberculosis. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
24. A Dharmadhikari, M Mphahlele, K Venter, K Weyer, SA Parsons, P Jensen, M First, E Nardell. Infectiousness of drug-resistant TB patients then and now: Riley revisited. Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
25. Van der Walt ML, Lancaster JL,  Weyer K, Becker P. Mortality among patients with multidrug-resistant tuberculosis (MDR-TB in South Africa. . Presented at: 39th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2008.
26. M van der Walt, G Coetzee. Rapid response to XDR-TB, WHO Global Task Force on XDR-TB, October 2006. Presented at TB Conference, Durban, July 2008.
27. Van der Walt ML, Lancaster JL,  Finlay A, Holtz TH, Weyer K. Default from TB and MDR-TB treatment in South Africa and the role of the patient-provider interaction. Presented at TB Conference, Durban, July 2008.
28. Kvasnovsky CL, Dalton TL, Lancaster JL, Brand JD, Ramjee A, Master I, October H, Siwisa O, Cegielski JP, Van der Walt ML. Geographic Diversity of MDR-TB Genotypes in Eastern Cape and Kwa-Zulu-Natal Provinces, South Africa from the “Preserving Effective TB Treatment Study“ (PETTS). Presented at TB Conference, Durban, July 2008. 
29. Van der Walt ML, Lancaster JL,  Weyer K, Becker P. Two-year follow-up of patients with multidrug-resistant tuberculosis (MDR-TB) in South Africa. Presented at TB Conference, Durban, July 2008. 
30. Mativandlela SPN, Muthivhi T, Van der Walt ML, Lall N, Meyer JJM, Hussein AAH. Evaluation of flavonoid compounds alone and in combination against Mycobacterium tuberculosis. Presented at TB Conference, Durban, July 2008.
31. Van der Walt ML. Rapid diagnosis of multi-drug-resistant (MDR) tuberculosis in South Africa with the Genotype® MTBDRplus assay. Presented at TB Conference, Durban, July 2008.
32. Van der Walt ML, Sewpersadh M. Field Evaluation of Rapid Diagnostics in Programme Settings. Presented at TB Conference, Durban, July 2008. 
33. Weyer K, Naidoo N and Uys M. Increasing access to HIV care for TB patients in SA : A best practice approach. Presented at:  38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa.  November  2007.
34. Van der Walt M, Coetzee G, Albert H, O’Brien R, Sewpersadh M, Weyer K, Roscigno G. The South African Demonstration Project on the use of a rapid MDR-TB assay for routine diagnosis of MDR-TB under TB Control Program settings. Presented at: 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa. November 2007.
35. Mphahlele M,  Syre H, Valvatne H, Stavrum R, Mannsåker T, Muthivhi T, Weyer K, Fourie PB, and Grewal HMS. Testing pyrazinamide resistance among South African Multidrug–Resistant Mycobacterium tuberculosis isolates. Presented at: 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa.  November 2007.
36. Nardell E, Weyer K, Jensen P, Parsons S, First M, Dharmadhikari A, Venter K, McMurray D. Transient tuberculosis infection in the naturally infected guinea pig model. Presented at:  38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa.  November 2007.
37. Nkhi E, Jensen P, Coggin W, Weyer K. Training on airborne infection control in high-burden TB-HIV settings. Presented at: 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa. November 2007.
38. Muthivhi TN, Mphahele MT, Weyer K.  Molecular Characterization of Ethionamide Resistance Amongst MDR Isolates of Mycobacterium tuberculosis. Presented at: 38th Union World Conference on Lung Health, to be held in Cape Town, South Africa. November 2007.
39. Venter K, Harrington A, Van Wyngaardt S, Verschoor JA, Weyer K. Progression of Pulmonary Tuberculosis after Intranasal Infection in BALB/c & C57BL/6 Mice.  Presented at: 38th Union World Conference on Lung Health, Cape Town, South Africa. November 2007.
40. Van der Walt ML, Lancaster J, Weyer K, Becker P. Mortality among patients with multidrug-resistant tuberculosis (MDR-TB) in South Africa. Presented at: 38th Union World Conference on Lung Health, Cape Town, South Africa. November 2007.
41. Weyer K, Naidoo N and Uys M. Improving access to HIV care for TB patients in SA : A best practice approach. 3rd Priorities in Aids Care and Treatment Conference Sandton Convention Centre., South Africa.   October  2007.
42. Dalton TL, Weyer K, Van der Walt M, Brand J, Lancaster J, Tupasi TE, Egos G, Gler M, Campos Caoili J, Leimane V, Skenders G, Ingrida S, Kliiman K, Hollo V, Bonilla C, Yagui M, Asencios L, Akksilp S, Wanpen, Taylor A, Ershova J, Cegielski JP.  Preserving Effective TB Treatment with Second-line drugs (PETTS): Prevalence of XDR-TB and other Second-line Drug Resistance among MDR-TB patients in 6 countries, 2005-2007. Presented at: 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa. November 2007.
43. Van der Walt M, Finlay AM, Lancaster J, Holtz TH, Weyer K. Risk factors for tuberculosis treatment default in South Africa differ between new and retreatment patients. Presented at:  38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa. November 2007.
44. Weyer K, Jensen P, Moll T, Nkhi E, Margot B, Nunn P, Parsons S, Pray R. Scaling-up infection control measures in the context of drug-resistant tuberculosis and HIV, Republic of South Africa, 2002. Presented at: 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa.  November  2007.
45. Weyer K. Transmission of Extreme Drug Resistant TB in South Africa and Implications for Infection Control in Health Care Settings.  Presented at 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007), Los Angeles, CA. February 2007
46. Farley J, Ram M, Pan B, Waldman S, Cassel G, Chaisson R, Weyer K, Van der Walt M. Outcomes of multi-drug resistant tuberculosis treatment amongst a South African Cohort with high HIV prevalence. Presented at: 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa. November 2007.
47. Weyer K, Nardell E, Jensen P, Robberts L, Parsons S, Venter K, First M, Wells C, Fourie B. MDR-TB transmission quantified in a state-of-the-art airborne infection research facility in South Africa. Presented at:  37th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2006.
48. Lancaster J, Finlay A, Van der Walt ML, Holtz TH, Miranda M, Pooe M, Laserson K, Wells CD, Weyer K. Reasons for tuberculosis treatment default, Republic of South Africa, 2002. Presented at:  37th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2006.
49. Finlay A, Lancaster J, Holtz TH, Van der Walt ML, Miranda M, Laserson K, Wells CD, Weyer K. Risk factors for tuberculosis treatment default, Republic of South Africa, 2002. Presented at:  37th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2006.
50. Weyer K, Naidoo N, Uys M, Nkhi E.  Increasing access to HIV care for TB patients in South Africa:  a best-practice approach.  Presented at: 36th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2005.
51. Weyer K. Strategies for managing rapid TB culture systems. Presented at: 36th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2005 (invited paper).
52. Weyer K, Parsons S, Jensen P, Nardell E, Robberts L, First M, Wells C.  Airborne infection research (AIR) Facility:  transmission dynamics of multidrug-resistant tuberculosis and evidence-based policies for environmental control. Presented at: 17th Conference of the International Society for Environmental Epidemiology, Johannesburg, South Africa.  September 2005 (invited paper).
53. Weyer K, Naidoo N. Improving Access to HIV Care for TB Patients: A Best-Practice Approach. Presented at: President’s Emergency Plan for AIDS Relief (PEPFAR) South Africa Partners Meeting, Durban, June 2005.
54. Weyer K, Parsons S.  Strategies and essential components of a successful infection control programme.  Presented at: Africa Conference on Hospital-Acquired Infections, Johannesburg, South Africa.  May 2005 (invited paper).
55. Weyer K, Naidoo N.  Improving access to HIV care for TB patients in South Africa:  a best-practice approach.  Presented at:  Implementing the comprehensive care and treatment programme for HIV and AIDS patients:  sharing experiences, Bloemfontein, South Africa. March 2005 (invited paper).
56. Weyer K, Levin J.  Implementation and management of operational research training.  Presented at:  35th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2004 (invited paper).
57. Weyer L, Brand J.  Importance of proficiency testing at regional laboratory network level.  Presented at:  35th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2004 (invited paper).
58. Weyer K, Van der Walt M, Lancaster J, Brand J, Levin J.  Treatment protocols and outcomes using a standardised treatment regimen for multidrug-resistant tuberculosis in South Africa.  Presented at:  35th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France.  October 2004 (invited paper).
59. Wong ML, Weyer K.  Demographics, presenting features and drug susceptibilities in a cohort of patients with tuberculosis.  Presented at:  South African Thoracic Society Conference, Durban, August 2004.
60. Austin J, Tsiouris S, Lancaster J, Coetzee D, Weyer K, Stein Z, Toro P, El-Sadr W.  A survey of latent TB infection in primary school children in Gugulethu, Cape Town:  lessons learned.  Presented at:  American Thoracic Society Congress, San Diego, USA. May 2004.
61. Finlay A, Van der Walt M, Holtz T, Thorpe L, Wells C, Weyer K.  Treatment outcomes of patients with multidrug-resistant tuberculosis in South Africa using a standardized regimen 1999 – 2000.  Presented at:  Infectious Diseases Society Conference, Boston. July 2004.
62. Weyer K.  Multidrug-resistant tuberculosis and HIV in South Africa.  Presented at:  Annual Meeting of the Tuberculosis Surveillance Research Unit, Geneva, Switzerland. April 2004 (invited paper).
63. Weyer K.  Standardised management of MDR-TB in South Africa.  Presented at:  Annual Meeting of the Tuberculosis Surveillance Research Unit, Geneva, Switzerland. April 2004 (invited paper).
64. Weyer K, Van der Walt M, Lancaster J.  MDR-TB in South Africa:  New strategies and policies.  Presented at:  Conference on tuberculosis control:  a multidisciplinary approach to research, policy and practice.  Bloemfontein, South Africa. November 2003 (invited paper).
65. Weyer K, Lancaster J, Levin J.  DOTSPacks for improved tuberculosis treatment delivery in South Africa.  34th World Conference on Lung Health of the IUATLD, Paris, France. October 2003.
66. Weyer K.  Laboratory safety:  balancing service with worker protection.  Presented at:  34th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Paris, France. October 2003 (invited paper).
67. Weyer K.  Culture and identification of Mycobacterium tuberculosis.  Presented at:  34th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Montréal, Canada.  October 2003 (invited paper).
68. Weyer K, Levin J, Van der Walt M, Brand J, Lancaster J.  MDR-TB management in South Africa.  Presented at: Meeting of the WHO DOTSPlus Working Group on MDR-TB, Paris, France. October 2003 (invited paper).   
69. Weyer K, A06-Treatment of TB: New data from clinical trials and demonstration projects, Presented at ATS 2003 – Seattle, Washington – 99th International Conference. May 2003 (invited paper).
70. Weyer K, Levin J, Van der Walt M, Brand J, Lancaster J.  Standardised management of multidrug-resistant tuberculosis (MDR-TB) patients in South Africa.  Presented at:  Annual Conference of the American Thoracic Society, Seattle, USA. May 2003 (invited paper).
71. Weyer K, Van der Walt M, Lancaster J, Brand J.  DOTSPlus for multidrug-resistant (MDR) tuberculosis in South Africa: results from the first cohort of patients treated with a standardised regimen under tuberculosis control programme conditions. Presented at: 33rd World Conference on Lung Health, Montreal, Quebec, Canada. October 2002.
72. Bopape MC, Koornhof HJ, Muthivhi TN, Fourie PB. Application of a mathematical model for multiple-drug combination testing against Mycobacterium tuberculosis, H37RV, 4th World Congress on Tuberculosis, Washington, DC, USA. June 2002.
73. Weyer K.  MDR TB in South Africa.  Presented at:  14th Conference of IUATLD Africa Region, Durban, South Africa. June 2002 (invited paper).
74. Muthivhi TN, Churchyard G, Koornhof HJ. Molecular identification of clones of drug-resistant mycobacterium tuberculosis strains in the mine may have implication for drug treatment. Presented at the International symposium on current developments in drug discovery for tuberculosis, Bangalore, India. January 2002.
75. Leimane V, Weyer K, Laserson KF, Thorpe L, Mitnick CD, Riekstina V, Zarovska E, Rich M, Fraser H, Alarcon E, Cegielski P, Grzemska M, Gupta R, Espinal M.  Speaking the same language:  proposed treatment outcome definitions for multidrug-resistant tuberculosis.  Proceedings of the 33rd World Conference on Lung Health of the IUATLD, Montréal, Canada, October 2001.  Int J Tuberc Lung Dis 2002; 6(10) (Suppl 1):  S137.
76. Weyer K, Lancaster J, Van der Walt M and the DOTSPlus Study Group of South Africa.  DOTSPlus for multidrug-resistant (MDR) tuberculosis in South Africa:  Results from the first cohort of patients treated with a standardised regimen under tuberculosis control programme conditions.  Int J Tuberc Lung Dis 2002; 6(10) (Suppl 1):  S138.

Invited plenary or keynote conference addresses / lectures

1. Weyer K. Transmission of extensively drug-resistant tuberculosis in South Africa and Implications for Infection Control in Health Care Settings. Presented at: 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007), Los Angeles, USA. February 2007 (invited Opening Symposium plenary paper).
2. Weyer K.  Multidrug-resistant tuberculosis in South Africa.  Presented at: Annual Conference of the South African National Tuberculosis Association, Durban, South Africa.  August 2003 (Key-note address).

Technical research reports

1. JD Venter, Technical Report for the Department of Pharmaceutics, School of Pharmacy, North-West University. Efficacy of Pheroid entrapped first line TB drugs as compared to free first line drugs in a murine model of acute tuberculosis, Innovation Fund Project T60042, March 2010.
2. Weyer K, Van der Walt ML, Final Performance Report: 2002/07/01 to 2007/06/30 - Cooperative Agreement Number U23/CCU021809: Report on Non-Competing Continuation Proposal to CDC. September 2007.
3. Van der Walt ML, Weyer K, Lancaster J, Becker P. Standardised management of MDR-TB in South Africa: Treatment outcomes of the second cohort. Report to National Department of Health, 2007. 
4. Van der Walt M, Lancaster J, Finlay A, Holtz T, Weyer K.  Risk Factors for Default from TB Treatment in South Africa. Pretoria: Medical Research Council, 2007. Report to South African National Department of Health.
5. Weyer K, Holtz T. Factors Associated with Default from Multidrug-Resistant Tuberculosis Treatment, South Africa, 1999-2001, Medical Research Council and Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 2005.
6. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in South Africa:  Final Report.  Pretoria:  Medical Research Council, 2004.  Report to:  Department of Health, 2004. 
7. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in Limpopo Province:  Final Report.  Pretoria:  Medical Research Council, 2003.  Report to:  Department of Health, 2003. 
8. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in Mpumalanga Province:  Final Report.  Pretoria:  Medical Research Council, 2003.   Report to:  Department of Health, 2003.
9. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in North West Province:  Final Report.  Pretoria:  Medical Research Council, 2003.  Report to:  Department of Health, 2003.
10. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in KwaZulu-Natal Province:  Final Report.  Pretoria, Medical Research Council, 2003.  Report to:  Department of Health, 2003.
11. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in Gauteng Province:  Final Report.  Pretoria: Medical Research Council, 2003.  Report to:  Department of Health, 2003.
12. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in the Western Cape Province:  Final Report.  Pretoria:  Medical Research Council, 2003.  Report to:  Department of Health, 2003.
13. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in the Eastern Cape Province:  Final Report.  Pretoria:  Medical Research Council, 2003.  Report to:  Department of Health, 2003.
14. Weyer K, Van der Walt M, Brand J, Lancaster J, Levin J.  Survey of Tuberculosis Drug Resistance in the Free State Province:  Final Report.  Pretoria: Medical Research Council, 2003.  Report to:  Department of Health, 2003.
15. Weyer K, Lancaster J, Levin J, Fourie PB.   Impact Of A Novel Drug Packaging Concept On Tuberculosis Treatment Delivery, Patient Adherence And Treatment Outcome.  Final report to:  Department for International Development (DFID), August 2002.
16. Van Der Walt M, Weyer K, Lancaster J, Levin J.  Transfer and Treatment Interruption Patterns Among Tuberculosis Patients In Demonstration And Training Districts In South Africa.  Final Study Report To:  Department For International Development (DFID) And Department Of Health.  MRC, Pretoria:  July 2002.
17. Weyer K.  National Survey Of Tuberculosis Drug Resistance In South Africa:  Second Progress Report, May 2002.  Report To:  Department Of Health, USAID, May 2002.
                         
    Weyer K, Brand J, Blumberg L.  Proficiency Testing And External Quality Assessment Of Tuberculosis Drug Susceptibility Testing At The National Reference Laboratory, Dar-Es-Salaam, Tanzania.  Report To:  WHO-Geneva And Tanzania TB & Leprosy Control Programme, February 2002.
18. Weyer K, Brand J, Blumberg L.  Proficiency Testing And External Quality Assessment Of Tuberculosis Drug Susceptibility Testing At The Central Reference Laboratory, Lilongwe, Malawi.  Report To:  WHO-Geneva And Malawi TB Control Programme, February 2002.
19. Weyer K, Brand J.  Proficiency Testing And External Quality Assessment Of Tuberculosis Drug Susceptibility Testing At The Central Reference Laboratory, Bulawayo, Zimbabwe.  Report To:  WHO-Geneva And Zimbabwe TB Control Programme, February 2002.
20. Weyer K, Brand J.  Proficiency Testing And External Quality Assessment Of Tuberculosis Drug Susceptibility Testing At The Chest Diseases Laboratory, Lusaka, Zambia.  Report To:  WHO-Geneva And ZAMBART TB Project, February 2002.

Dissertations and theses

1. Mativandlela Sannah Patience Nkami, Antituberculosis activity of flavonoids from Galenia africana L. var. Africana, 2009, Degree Awarded: PhD
2. Mphahlele M.  Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from South African pulmonary tuberculosis patients. University of Bergen. ISBN: 82-7815-124-5 (Master’s thesis). 2005.
3. Naidoo N.  Understanding First Year University Students' Perception of Poster and Television Health Communication Messages on HIV/AIDS. (University of KwaZulu-Natal). (Master’s thesis). 2007.
4. R Lemmer. The Tuberculosis Control Programme in the Industry in Swaziland: A Critical Evaluation. MMED Department of Community Health, SHSPH, Faculty of Medicine, University of Pretoria.   2004. (Promotor K Weyer).
5. DL Dalton.  TB in the Venda population:  association with vitamin D receptor polymorphism.  MSc, Rand Afrikaans University.  2003.
6. SZ Mokheti.  Molecular epidemiology of Mycobacterium tuberculosis strains from the Free State and Northern Cape provinces, South Africa.  Master of Medical Science (Microbiology), University of the Free State. 2004.